A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results